73 related articles for article (PubMed ID: 17853722)
1. [The use of erythropoietin beta, two to three times per week, once per week and once every other week: meta-analysis of two clinical trials].
Pljesa S
Med Pregl; 2007; 60(3-4):123-7. PubMed ID: 17853722
[TBL] [Abstract][Full Text] [Related]
2. Safety and Efficacy of Methoxy Polyethylene Glycol-epoetin Beta in Anemia Treatment in Patients on Hemodialysis: a Macedonian Experience.
Kacarska-Fotevska II; Volckova N; Ilievska K; Donev D
Med Arch; 2020 Apr; 74(2):109-114. PubMed ID: 32577051
[TBL] [Abstract][Full Text] [Related]
3. Relationship between protein-energy wasting in adults with chronic hemodialysis and the response to treatment with erythropoietin.
González-Ortiz A; Correa-Rotter R; Vázquez-Rangel A; Vega-Vega O; Espinosa-Cuevas Á
BMC Nephrol; 2019 Aug; 20(1):316. PubMed ID: 31412807
[TBL] [Abstract][Full Text] [Related]
4. Investigation on the feasibility of large-volume autologous red blood cells donation: A pilot trial in a small cohort of Chinese.
Wu J; Chen G; Wang L; Wang P; Han Y; Yang L; Ouyang X
J Clin Apher; 2023 Aug; 38(4):447-456. PubMed ID: 36950971
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the hemoglobin variability in non-chronic kidney disease or end-stage renal disease participants and patients with CKD and ESRD.
Plappert C; Müller HJ; Haubitz M; Höcker R; Weißer H; Benöhr P
Clin Nephrol; 2024 Apr; 101(4):171-180. PubMed ID: 38329918
[TBL] [Abstract][Full Text] [Related]
6. Effect of Ziltivekimab on Determinants of Hemoglobin in Patients with CKD Stage 3-5: An Analysis of a Randomized Trial (RESCUE).
Pergola PE; Davidson M; Jensen C; Mohseni Zonoozi AA; Raj DS; Andreas Schytz P; Tuttle KR; Perkovic V
J Am Soc Nephrol; 2024 Jan; 35(1):74-84. PubMed ID: 38088558
[TBL] [Abstract][Full Text] [Related]
7. Effect of periodic transfusion on erythropoietin concentration in end stage renal disease.
Hong SY; Yang DH
Korean J Intern Med; 1992 Jul; 7(2):122-9. PubMed ID: 1306073
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of roxadustat in maintenance hemodialysis patients with erythropoietin-hyporesponsive anemia.
Wang X; Cai H; Xu H; Chen L
Clin Nephrol; 2024 Jan; 101(1):25-33. PubMed ID: 37969110
[TBL] [Abstract][Full Text] [Related]
9. Implications of a reduction in the hemoglobin target in erythropoiesis-stimulating agent-treated hemodialysis patients.
Nguyen TV; Goldfarb DS
Nephron Extra; 2011 Jan; 1(1):212-6. PubMed ID: 22470394
[TBL] [Abstract][Full Text] [Related]
10. A randomized, masked study of weekly erythropoietin dosing in preterm infants.
Ohls RK; Roohi M; Peceny HM; Schrader R; Bierer R
J Pediatr; 2012 May; 160(5):790-5.e1. PubMed ID: 22137666
[TBL] [Abstract][Full Text] [Related]
11. Effect of vitamin D supplementation on management of anemia in hemodialysis patients with vitamin D deficiency: A double-blind, randomized, controlled trial.
Emarah SM; Ahmed MAER; El Kannishy GM; Abdulgalil AE
Hemodial Int; 2024 Jan; 28(1):51-58. PubMed ID: 37853507
[TBL] [Abstract][Full Text] [Related]
12. Optimal and continuous anaemia control in a cohort of dialysis patients in Switzerland.
Mathieu CM; Teta D; Lötscher N; Golshayan D; Gabutti L; Kiss D; Martin PY; Burnier M
BMC Nephrol; 2008 Dec; 9():16. PubMed ID: 19077225
[TBL] [Abstract][Full Text] [Related]
13. Ratio of baseline erythropoietin (EPO) level and corrected reticulocyte count as an indicator for a favourable response to recombinant human erythropoietin (rhEPO) therapy in anaemic cancer patients.
Charuruks N; Voravud N; Limpanasithikul W
J Clin Lab Anal; 2001; 15(5):260-6. PubMed ID: 11574955
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of two dose schedules of C.E.R.A. (Continuous Erythropoietin Receptor Activator) in anemic patients with advanced non-small cell lung cancer (NSCLC) receiving chemotherapy.
Hirsh V; Glaspy J; Mainwaring P; Manegold C; Ramlau R; Eid JE
Trials; 2007 Mar; 8():8. PubMed ID: 17341293
[TBL] [Abstract][Full Text] [Related]
15. A Safe and Easy Introduction of Darbepoetin-Alpha in Patients Receiving Maintenance Hemodialysis and Epoetin Monotherapy: A "Half-and-Half" Combination Therapy.
Shimamatsu K; Inamasu H
Curr Ther Res Clin Exp; 2013 Jun; 74():5-8. PubMed ID: 24384988
[TBL] [Abstract][Full Text] [Related]
16. How the duration period of erythropoietin treatment influences the oxidative status of hemodialysis patients.
Dimitrijevic ZM; Cvetkovic TP; Djordjevic VM; Pavlovic DD; Stefanovic NZ; Stojanovic IR; Paunovic GJ; Velickovic-Radovanovic RM
Int J Med Sci; 2012; 9(9):808-15. PubMed ID: 23136545
[TBL] [Abstract][Full Text] [Related]
17. Hemoglobin variability in patients receiving EPO and roxadustat during maintenance hemodialysis: a self-control study.
Wang X; Zhu N; Zeng W; Wang P
Eur Rev Med Pharmacol Sci; 2024 Jan; 28(1):303-309. PubMed ID: 38235900
[TBL] [Abstract][Full Text] [Related]
18. Erythropoietin, uncertainty principle and cancer related anaemia.
Clark O; Adams JR; Bennett CL; Djulbegovic B
BMC Cancer; 2002 Sep; 2():23. PubMed ID: 12270068
[TBL] [Abstract][Full Text] [Related]
19. Association Between the Polymorphism of Angiotensin-Converting Enzyme Gene and Interleukin-1 Beta Gene and the Response to Erythropoietin Therapy in Dialysis Patients with Anemia.
Dzekova-Vidimliski P; Eftimovska-Otovikj N; Nikolov IG; Selim G; Rambabova-Bushljetik I; Pushevski V; Karanfilovski V; Matevska-Geshovska N; Dimovski A
Balkan J Med Genet; 2023 Dec; 26(2):27-34. PubMed ID: 38482261
[TBL] [Abstract][Full Text] [Related]
20. The Relation of Erythropoietin Towards Hemoglobin and Hematocrit in Varying Degrees of Renal Insufficiency.
Panjeta M; Tahirovic I; Karamehic J; Sofic E; Ridic O; Coric J
Mater Sociomed; 2015 Jun; 27(3):144-8. PubMed ID: 26236158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
